Theravance Respiratory Company, LLC

Theravance, Inc.

Daniel Byun

Adam D Hughes

John R Jacobsen

Melissa Fleury

Yan Chen

Eric L Stangeland

Rose Yen

Richard D Wilson

Eric Strangeland

Richard Wilson

The invention relates to a pharmaceutical composition comprising an isotonic aqueous solution comprising a compound of formula I: or a pharmaceutically acceptable salt thereof.

Diamide compounds having muscarinic receptor antagonist and &#x3b2;2 adrenergic receptor agonist activity

Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agonist activity

The invention relates to a pharmaceutical composition comprising an isotonic aqueous solution comprising from about 0.05 &#x3bc;g/mL to about 10 mg/mL of a compound of formula I: or a pharmaceutically acceptable salt thereof.

Diamide compounds having muscarinic receptor antagonis and beta2 adrenergic receptor agonist activity

This invention relates to a compound of formula I: 

[object Object]

The invention provides diamide compounds having muscarinic receptor antagonist and &#x3b2;adrenergic receptor agonist activity, pharmaceutical compositions thereof, and methods of treatment using the same.

Diamide compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity

This invention relates to a compound of formula I:  or a pharmaceutically acceptable salt thereof. Such compounds possess both muscarinic receptor antagonist and &#x3b2;adrenergic receptor agonist activities. The invention also relates to pharmaceutical compositions comprising such compounds, processes and intermediates for preparing such compounds, and methods of using such compounds as bronchodilating agents to treat pulmonary disorders.

Growing community of inventors

Alameda, CA, United States of America

Daniel Byun